Compare FGNX & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGNX | XLO |
|---|---|---|
| Founded | 1932 | 2016 |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 49.8M |
| IPO Year | N/A | 2021 |
| Metric | FGNX | XLO |
|---|---|---|
| Price | $6.20 | $8.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $35.00 | $28.00 |
| AVG Volume (30 Days) | ★ 121.2K | 38.0K |
| Earning Date | 05-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | $650.31 | N/A |
| Revenue Next Year | N/A | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $1.59 | $0.46 |
| 52 Week High | $18.42 | $9.89 |
| Indicator | FGNX | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 61.11 | 44.74 |
| Support Level | $6.52 | $7.47 |
| Resistance Level | $7.65 | $8.80 |
| Average True Range (ATR) | 0.59 | 0.37 |
| MACD | 0.23 | -0.09 |
| Stochastic Oscillator | 94.37 | 9.70 |
FG Nexus Inc operates through two primary segments: Digital Assets and Merchant Banking, with Digital Assets contributing the majority of revenue. The Company functions as a digital asset treasury, mainly holding Ethereum (ETH) and exploring opportunities in the tokenization of real-world assets, leveraging ETH as the foundation for digital finance, stablecoins, DeFi, and tokenized assets. The Merchant Banking segment offers strategic, administrative, and regulatory support to newly formed SPACs through the Company's SPAC platform.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.